These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
Data highlight ambition to transform prevention and treatment for serious bacterial infections and develop novel preventative strategies for respiratory viral infections
EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Zidavi is recommended by the Infectious Disease Society of America
Subscribe To Our Newsletter & Stay Updated
